Grau-Jurado Pol, Mostafaei Shayan, Xu Hong, Mo Minjia, Petek Bojana, Kalar Irena, Naia Luana, Kele Julianna, Maioli Silvia, Pereira Joana B, Eriksdotter Maria, Chatterjee Saikat, Garcia-Ptacek Sara
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden.
Departmenet of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
J Alzheimers Dis. 2025 Feb;103(3):931-940. doi: 10.1177/13872877241307870. Epub 2025 Jan 8.
Medications for comorbid conditions may affect cognition in Alzheimer's disease (AD).
To explore the association between common medications and cognition, measured with the Mini-Mental State Examination.
Cohort study including persons with AD from the Swedish Registry for Cognitive/Dementia Disorders (SveDem). Medications were included if they were used by ≥5% of patients (26 individual drugs). Each follow-up was analyzed independently by performing 100 Monte-Carlo simulations of two steps each 1) k-means clustering of patients according to Mini-Mental State Examination at follow-up and its decline since previous measure, and 2) Identification of medications presenting statistically significant differences in the proportion of users in the different clusters.
15,428 patients (60.38% women) were studied. Four clusters were identified. Medications associated with the best cognition cluster (relative to the worse) were atorvastatin (point estimate 1.44 95% confidence interval [1.15-1.83] at first follow-up, simvastatin (1.41 [1.11-1.78] at second follow-up), warfarin (1.56 [1.22-2.01] first follow-up), zopiclone (1.35 [1.15-1.58], and metformin (2.08 [1.35-3.33] second follow-up. Oxazepam (0.60 [0.50-0.73] first follow-up), paracetamol (0.83 [0.73-0.95] first follow-up), cyanocobalamin, felodipine and furosemide were associated with the worst cluster. Cholinesterase inhibitors were associated with the best cognition clusters, whereas memantine appeared in the worse cognition clusters, consistent with its indication in moderate to severe dementia.
We performed unsupervised clustering to classify patients based on their current cognition and cognitive decline from previous testing. Atorvastatin, simvastatin, warfarin, metformin, and zopiclone presented a positive and statistically significant associations with cognition, while oxazepam, cyanocobalamin, felodipine, furosemide and paracetamol, were associated with the worst cluster.
用于治疗共病的药物可能会影响阿尔茨海默病(AD)的认知功能。
探讨使用简易精神状态检查表测量的常见药物与认知之间的关联。
队列研究,纳入瑞典认知/痴呆症登记处(SveDem)的AD患者。如果某种药物的使用患者比例≥5%(26种单一药物),则将其纳入研究。每次随访均通过对以下两个步骤进行100次蒙特卡洛模拟来独立分析:1)根据随访时的简易精神状态检查表及其自上次测量以来的下降情况,对患者进行k均值聚类;2)识别在不同聚类中使用者比例存在统计学显著差异的药物。
共研究了15428名患者(60.38%为女性)。识别出四个聚类。与认知最佳聚类(相对于最差聚类)相关的药物有阿托伐他汀(首次随访时的点估计值为1.44,95%置信区间[1.15 - 1.83])、辛伐他汀(第二次随访时为1.41[1.11 - 1.78])、华法林(首次随访时为1.56[1.22 - 2.01])、佐匹克隆(1.35[1.15 - 1.58])和二甲双胍(第二次随访时为2.08[1.35 - 3.33])。奥沙西泮(首次随访时为0.60[0.50 - 0.73])、对乙酰氨基酚(首次随访时为0.83[0.73 - 0.95])、氰钴胺、非洛地平和呋塞米与最差聚类相关。胆碱酯酶抑制剂与认知最佳聚类相关,而美金刚出现在认知较差的聚类中,这与其用于中度至重度痴呆的适应证一致。
我们进行了无监督聚类,以根据患者当前的认知情况及其与上次测试相比的认知下降情况对患者进行分类。阿托伐他汀、辛伐他汀、华法林、二甲双胍和佐匹克隆与认知呈正相关且具有统计学显著意义,而奥沙西泮、氰钴胺、非洛地平、呋塞米和对乙酰氨基酚与最差聚类相关。